Longeveron (LGVN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
15 Jul, 2026Opening remarks and agenda
The meeting was called to order by the Executive Chairman, welcoming attendees to the fifth annual virtual meeting and outlining procedures for stockholder participation and questions.
Executive officers and independent auditors were introduced, with auditors available for questions.
Procedural matters included proof of notice, availability of proxy materials, and confirmation of quorum.
Board and executive committee updates
Three Class II directors were nominated for election to serve three-year terms expiring at the 2029 annual meeting.
No additional nominations were received before the deadline.
Shareholder proposals
Proposals included electing directors, increasing authorized Class A shares to 175 million, approving a reverse stock split (1:2 to 1:20), amending the 2021 Incentive Award Plan to add 5 million shares, ratifying the appointment of CBIZ as auditors, and authorizing adjournment if needed for further proxy solicitation.
Latest events from Longeveron
- ELPIS II topline data are anticipated in Q3 2026 as laromestrocel advances across four indications.LGVN
Investor presentation - ELPIS I showed 100% five-year transplant-free survival in treated HLHS patients.LGVN
Investor presentation - Laromestrocel advances across three indications, with pivotal trials planned or underway.LGVN
Investor presentation - Pivotal HLHS and planned Alzheimer's and PDCM trials anchor laromestrocel's pipeline.LGVN
Investor presentation - Laromestrocel spans three indications, with ELPIS II pivotal if positive.LGVN
Investor presentation - Lomecel-B advances across three indications, with encouraging HLHS, AD and frailty data.LGVN
Investor presentation - Laromestrocel's late-stage data and PRV eligibility position it for major value inflection.LGVN
Investor presentation - Q2 2026 net loss rose to $6.1M as cash runway extends into Q4 2026 ahead of key trial results.LGVN
Q2 2026 - Directors elected, incentive plan amended, and auditors ratified at the annual meeting.LGVN
AGM 2024